Sinopharm Vaccine Efficacy Study For Children – Abu Dhabi World Online

Sinopharm Vaccine Efficacy Study For Children

The Ministry of Health and Prevention (MOHAP) has introduced {that a} bridge examine for youngsters aged 3 to 17 to obtain the Sinopharm vaccine is being held.

The UAE is the primary nation within the MENA area to conduct a examine on the vaccine efficacy for this age group.

Over the previous few months, China, United States, United Kingdom and India, have additionally began scientific trials for youngsters.

900 youngsters from completely different nationalities will likely be assessed on their immunity after getting the vaccine. The youngsters will likely be carefully monitored with dad or mum’s consent to make sure their security.

Information will consistently be given to folks and kids.

The Department of Health in Abu Dhabi has authorised the examine with all medical protocols in place, below the supervision of MOHAP.

Vaccinations for people aged 18 and above have been ongoing to supply immunity from the virus. With the rise in mutations, in addition to the variety of instances in youngsters, the examine will assist defend youngsters in addition to these round them.

The outcomes from the examine will likely be made out there to the general public on completion and can then kind the premise for when college students can return to in-person studying at faculties.

Dr Nawal Al Kaabi, Chairwoman of the National COVID-19 Clinical Management Committee stated, “Children are the cornerstone of any society and the future of any nation. As more and more people are vaccinated in the UAE, we want to make sure that our children are able to receive the vaccine safely. This is why when we designed the Sinopharm immune bridge study we focused on ensuring all care is given to our young volunteers throughout the journey. We want both children and parents to understand every step of the process and also to know that we will be with them, supporting them, answering every question they may have, at any time.”

Source link

Back to top button